Posted by Michael Wonder on 14 Sep 2021
ISA Pharmaceuticals receives fast track designation for lead product ISA101b
14 September 2021 - Fast track designation for the treatment of recurrent and metastatic HPV16 positive oropharyngeal cancer to improve survival and delay progression.
ISA announces that the U.S. FDA has granted fast track designation to its lead product ISA101b, for the treatment of recurrent and metastatic oropharyngeal cancer that is positive for human papilloma virus type 16.
